A Case Report of Cytarabine-Induced Red Ear Syndrome.
| Autor: | Botros M; Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, USA., De La Rosa A; Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, USA., Nadella S; Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, USA., Chang AY; Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, USA., Maharaj SS; Hematology and Oncology, Texas Tech University Health Sciences Center El Paso, El Paso, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2023 Nov 12; Vol. 15 (11), pp. e48707. Date of Electronic Publication: 2023 Nov 12 (Print Publication: 2023). |
| DOI: | 10.7759/cureus.48707 |
| Abstrakt: | Cytarabine is an antimetabolite used in the treatment of acute myeloid leukemia which acts by inhibiting DNA synthesis and subsequently cell division. It works on rapidly dividing cells, for that reason, it affects cancer cells, bone marrow and skin cells. Cytarabine has variable cutaneous side effects, the most common one is palmar-plantar erythema which usually presents with a tingling sensation around 5-7 days after cytarabine initiation, followed by erythema and tenderness. Auricular erythema is a rare subtype involving bilateral ears which often presents as ear redness and tenderness as described in the presented case. It is unclear if the skin side effects are related to cytarabine dose or plasma concentration. Most cases of auricular erythema have a benign course and resolve spontaneously. Treatment is mainly conservative. Steroids and antihistamines can be used to speed up recovery given that the pathophysiology is thought to be immediate or due to a delayed hypersensitivity reaction to cytarabine. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Botros et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|